期刊文献+

“双通道”模式下不同支付方式对医保预算的影响分析:以耐受药肺结核治疗为例 被引量:7

Budget Impact Analysis of Different Payment Methods on the Medical Insurance under the “Dual-Channel” Mode Taking the Treatment of Multi-drug Resistant Tuberculosis as an Example
原文传递
导出
摘要 目的:以耐多药肺结核治疗为例,预测“双通道”模式下不同支付方式对医保基金预算和患者负担的影响,并为该模式在地方层面的落地方式提供参考。方法:基于医保支付方视角构建预算影响分析模型,对照考虑单行支付、门诊参照住院两种支付方式,计算7种治疗方案在住院、门诊中可能产生的报销费用,预测2022—2024年江苏省医保基金支出与患者负担的变化情况。结果:单行支付模式下,江苏省耐多药肺结核患者预计医保支出增额分别为779万、787万和795万,患者人均负担降低17 800~25 200元;门诊参照住院模式下,各年医保支出增额分别为1 208万、1 219万和1 230万,患者人均负担降低27 600~39 100元。结论:“双通道”管理政策的各支付方式在不同程度上增加了医保支出,减轻了患者负担。下一步可探索不同支付方式之间的可替代性,实现基金可持续与患者获益的平衡。 Objective:Taking multidrug-resistant tuberculosis as an example, it is estimated that the impact of different payment methods on the budget of medical insurance fund and the burden of patients under the “dual-channel” mode is predicted, and it provides a reference for the landing method of the model at the local level.Methods:Based on the perspective of the medical insurance payer, the budget impact analysis model was constructed. The possible reimbursement expenses of 7 treatment schemes in inpatient and outpatient clinics were calculated by considering the single-line payment and outpatient as references to the two payment methods, and the change of the expenditure and patient burden of the medical insurance fund in Jiangsu Province from 2022 to 2024 was predicted.Results:Under the one-line payment model, the estimated increases in medical insurance expenditure for patients with multidrug-resistant tuberculosis in Jiangsu Province were 7.79 million, 7.87 million and 7.95 million, respectively, and the per capita burden of patients decreased by 17 800-25 200 yuan.Conclusion:The payment methods of the “dual-channel” management policy have increased the cost of health insurance to varying degrees and reduced the burden on patients. The next step is to explore alternatives between different payment methods and to achieve a balance between the sustainability of the fund and the benefits to patients.
作者 袁惜方 尚培治 张冬儿 唐文熙 李霞 YUAN Xi-fang;SHANG Pei-zhi;ZHANG Dong-er(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing,211198,China;不详)
出处 《中国卫生经济》 北大核心 2022年第5期32-35,共4页 Chinese Health Economics
基金 江苏省医保研究会课题(2021-02) 江苏省研究生科研与实践创新计划项目(KYCX21-0691)。
关键词 医保基金管理“双通道”模式 耐多药肺结核 “dual channel”management medical insurance fund disease economic burden multi-drug resistant tuberculosis
  • 相关文献

参考文献4

二级参考文献57

  • 1李亮,傅瑜.耐药结核病的现状与展望[J].结核病健康教育,2008(1):17-20. 被引量:3
  • 2WorldHealth Organization Stop TB Department.耐药结核病规划管理指南2008年紧急修订版[EB/OL].[2008-09-07].http://whqlibdoc.who.int/publications/2008/978924154758l_chi.pdf.
  • 3World Health Organization. Global tuberculosis control : Epidemiology, strategy, financing[R]: WHO report 2009. WHO/HTM/ TB/2009.
  • 4耐多药结核高负担国家部长级会议.解决预防耐多药,广泛耐药结核病与加强控制并扩大患者治疗的关键瓶颈问题[EB/OL].[2009-08-10].http://www.who.int/tb/tlenecks-full-v-ersion_zh.pdf.
  • 5Kawabata K, Xu K, Can-in C. Prevent impoverishment through protection against catastrophic health expenditure[J].Geneva.Bulletion of the world health organization, 2002(8) : 80.
  • 6Suarez AG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of Standardized second line drug treatment for chronic tuberculosis patients: a national cohort study in Peru[J]. The Lancet. 2002(359): 181-190.
  • 7胡明礼.国内莫西沙星不良反应文献分析[J].药学服务与研究,2007,7(4):281-283. 被引量:41
  • 8张洁,谭浩.利福平与其他药物相互作用研究进展[J].天津药学,2009,21(1):69-72. 被引量:14
  • 9肖和平.耐药结核病化学治疗指南(2009)[J].中国防痨杂志,2010,32(4):181-198. 被引量:137
  • 10孙强,闫赟,边学峰,张加胜,李文婧,陈诚,赵津,李仁中.耐多药肺结核患者医疗费用及经济负担分析[J].中国卫生经济,2011,30(1):33-35. 被引量:29

共引文献334

同被引文献64

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部